Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 5NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Radiotherapy 13Cisplatin 8Cytarabine 7carfilzomib 5Specimen Handling 5Paclitaxel 5Dexamethasone 5Methotrexate 4Lapatinib 4Gemcitabine 4Fluorouracil 4Docetaxel 4Brachytherapy 4Biopsy 4venetoclax 3pomalidomide 3Temozolomide 3Radiotherapy, Conformal 3Leucovorin 3Irinotecan 3Etoposide 3Cyclophosphamide 3Carboplatin 3neratinib 2merphos 2Vincristine 2Radiation 2Polymerase Chain Reaction 2Oxaliplatin 2Immunohistochemistry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × NETWORK × neratinib × Clear all
NCT02236000 2023-01-26

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

NSABP Foundation Inc

Phase 1/2 Completed
49 enrolled 17 charts
Breast

Breast Neoplasms

NCT01960023 2021-10-27

Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer

NSABP Foundation Inc

Phase 1/2 Withdrawn
Gastrointestinal

Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡